Resource impact summary report

Download (PDF)

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'population and treatments', 'unit costs', 'capacity' and 'adverse events' worksheets in the template to reflect local data and assumptions.

Guidance recommendation

See NICE's recommendation on venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia.

Financial and capacity resource impact

The key drivers of resource impact are that:

the treatment duration of venetoclax with obinutuzumab is shorter than comparator treatments
the number of administrations in each cycle is more than comparator treatments
the administration time for obinutuzumab is longer than other treatments because it is administered intravenously, rather than orally for the other drugs
there are reduced monitoring requirements for venetoclax with obinutuzumab because of cardiac monitoring requirements for venetoclax with ibrutinib.

The company has a commercial arrangement. This makes venetoclax with obinutuzumab available to the NHS at a discount.

Users can input the confidential price of venetoclax with obinutuzumab and amend other variables in the resource impact template.

The payment mechanism for the technology is determined by the responsible commissioner and depends on whether the technology is classified as high cost.

We expect that the resource impact of implementing the recommendations in England will be less than £5 million per year (or about £8,700 per 100,000 people in the population, based on a population in England of 57.7 million people). This is because the technology is an additional treatment option and the overall cost of treatment will be similar for this population.

The drug is already available to the NHS through the Cancer Drugs Fund (CDF) so we do not think practice will change substantially as a result of this guidance, other than being available through routine commissioning rather than the CDF.

For further analysis or to calculate the financial and capacity impact, see the resource impact template.

Eligible population for venetoclax with obinutuzumab

Table 1 shows the population who are eligible for venetoclax with obinutuzumab and the number of people who are expected to have it in each of the next 3 years, excluding forecast population growth.

**Table 1 Population expected to be eligible for and have venetoclax with obinutuzumab in England**
Eligible population and uptake	Number of people eligible for venetoclax with obinutuzumab	Uptake for venetoclax with obinutuzumab (%)	Number of people having venetoclax with obinutuzumab each year
Current practice without venetoclax with obinutuzumab in routine commissioning	700	28	200 (in CDF)
Year 1	700	28	200 (in routine commissioning)
Year 2	700	28	200 (in routine commissioning)
Year 3	700	28	200 (in routine commissioning)

Abbreviations: CDF, Cancer Drugs Fund.

The market share for venetoclax with obinutuzumab is based on current use in the CDF from Blueteq data.

Treatment options for the eligible population

The comparator treatment for the eligible population is venetoclax with ibrutinib.

Venetoclax with obinutuzumab has a shorter treatment duration than the comparator treatment. Venetoclax has a fixed duration of treatment of 12 cycles in both regimens. But in the comparator, the ibrutinib element of the regimen is given for 3 cycles without venetoclax at the start of treatment. Obinutuzumab is the only intravenously administered drug used in this population. Venetoclax and ibrutinib are both oral tablets.

For more information about the treatments, such as dose and average treatment duration, see the resource impact template.

Key information

Table 2 Key information

Time from publication to routine commissioning funding	90
Programme budgeting category	PBC 02I - Cancer, Haematological
Commissioner(s)	NHS England
Provider(s)	NHS hospital trusts
Pathway position	First line

About this resource impact summary report

This resource impact summary report accompanies the NICE technology appraisal guidance on venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia and should be read with it.

ISBN: 978-1-4731-7966-0

This page was last updated: 07 January 2026